OpGen specializes in rapid diagnostics for infectious diseases, addressing antibiotic-resistant strains.

OpGen (NASDAQ:OPGN) focuses on the development and commercialization of innovative solutions for combating infectious diseases, with an emphasis on antibiotic-resistant strains. The company pioneers cutting-edge technologies, including rapid diagnostics and informatics tools, aimed at enabling healthcare providers to quickly identify and treat infections. This endeavor significantly contributes to global health security by addressing one of the most pressing challenges in the medical field. OpGen's projects span advanced diagnostic tests and data analytics platforms, all designed to improve patient outcomes and reduce healthcare costs. Objectives revolve around expanding its product portfolio, enhancing diagnostic accuracy, and fostering partnerships to reach broader markets.
GET YOUR GRAFA EDGE NOW
Sign up free to follow this company
We'll switch on a 30-day Edge trial as a welcome gift